1. Scrip

Frontrunner Kymera Claims Proof-Of-Concept For Protein Degrader Platform

Results From Sanofi-Partnered Asset

 
• By Andrew McConaghie

Kymera has unveiled the first placebo-controlled data from a protein degradation candidate, adding to heightened expectations for the novel modality.

MIT Hockfield Court, Stata Center in Kendall Square, Cambridge MA
Cambridge, MA -based Kymera has reached 'proof of concept' six years after its launch. • Source: Alamy

Kymera Therapeutics, one of the leaders in the hotly tipped targeted protein degradation (TPD) field, has unveiled early data which it claims are proof-of-concept for its lead candidate and its platform.

Kymera’s lead candidate, KT-474, achieved and exceeded a target degradation of 85% of the IRAK4 protein, key to many inflammatory conditions, producing the results in a placebo-controlled Phase I single...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.